Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

WHAT'S NEW

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jul 9 2020

Full Issue

J&J Urged To Stop Selling Talc-Based Baby Powder Worldwide

Also in the news: Botox, Roundup, mitochondrial research and a Q&A with a disease detective.

Reuters: Nonprofits Urge Johnson & Johnson To Halt Sales Of Baby Powder Globally 

More than 170 nonprofit groups on Wednesday called for Johnson & Johnson to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos, according to a statement from advocacy group Black Women for Wellness. (O'Donnell, 7/8)

Stat: International Trade Judge Suggests A 10-Year Ban On A Botox Rival

In a boost for AbbVie (ABBV), a U.S. International Trade Commission judge this week made an initial determination that sales of a competing version of its best-selling Botox treatment should be banned for 10 years. The ruling came in response to a complaint filed last year by Allergan, which AbbVie has since acquired, that a pair of rival companies — Evolus (ELOS) and Daewoong Pharmaceuticals — allegedly stole trade secrets that were used to develop a new wrinkle-smoothing product. A final decision from the ITC, however, is not due until November. (Silverman, 7/8)

The New York Times: Judge Puts Cloud Over Settlement Of Roundup Cancer Claims 

An agreement to pay more than $10 billion to settle thousands of claims that the popular weedkiller Roundup causes cancer is at risk of unraveling. Although the bulk of the complex deal between Roundup’s manufacturer, the German conglomerate Bayer, and a raft of plaintiff lawyers does not require court approval, one crucial piece does: a plan for handling future claims from customers who develop the form of cancer known as non-Hodgkin’s lymphoma. (Cohen, 7/7)

In science news —

The New York Times: 8 Questions From A Disease Detective On The Pandemic’s Origins 

For decades, Dr. Daniel R. Lucey, an infectious disease specialist at Georgetown University, has crisscrossed the globe to study epidemics and their origins. His attention now is on the Covid-19 pandemic, which first came to public notice late last year in Wuhan, China. Its exact beginnings are sufficiently clouded that the World Health Organization has begun a wide inquiry into its roots. The advance team is to leave for China this weekend, and Dr. Lucey has publicly encouraged the health agency to address what he considers eight top questions. (Broad, 7/8)

Stat: Gene-Editing Find Could Point To Cures For Mitochondrial Diseases 

Biologist David Liu was in the middle of his morning commute to the Broad Institute two summers ago when he opened the email. We just discovered a new toxin made by bacteria, explained the note from a researcher Liu had never spoken to, and it “might be useful for something you guys do.” Intrigued, Liu phoned the sender, biologist Joseph Mougous of the University of Washington, and it quickly became clear that the bacterial toxin had a talent that was indeed useful for what Liu does: invent ways to edit genes. On Wednesday, they and their colleagues reported in Nature that they had turned the toxin into the world’s first editor of genes in cell organelles called mitochondria. (Begley, 7/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF